Atika Capital Management LLC Invests $4.53 Million in Teva Pharmaceutical Industries Ltd. $TEVA

Atika Capital Management LLC purchased a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 224,000 shares of the company’s stock, valued at approximately $4,525,000.

Other institutional investors also recently added to or reduced their stakes in the company. Cromwell Holdings LLC increased its stake in shares of Teva Pharmaceutical Industries by 40.3% during the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares during the last quarter. Advisors Asset Management Inc. bought a new position in Teva Pharmaceutical Industries during the second quarter valued at $41,000. Rothschild Investment LLC increased its position in Teva Pharmaceutical Industries by 97.0% in the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after buying an additional 1,348 shares during the last quarter. JFS Wealth Advisors LLC increased its position in Teva Pharmaceutical Industries by 257.1% in the third quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after buying an additional 2,000 shares during the last quarter. Finally, LRI Investments LLC raised its stake in shares of Teva Pharmaceutical Industries by 246.0% in the third quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock valued at $57,000 after buying an additional 2,000 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $30.46 on Thursday. The firm has a market capitalization of $35.02 billion, a P/E ratio of 25.38, a PEG ratio of 10.55 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. The business has a fifty day moving average price of $33.00 and a 200-day moving average price of $26.53.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same period in the previous year, the company posted $0.71 EPS. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 9,533 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $301,910.11. Following the sale, the insider owned 107,711 shares of the company’s stock, valued at approximately $3,411,207.37. This represents a 8.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Brian Savage sold 1,127 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the sale, the insider owned 10,914 shares in the company, valued at $345,646.38. This represents a 9.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 948,499 shares of company stock valued at $30,897,071. Company insiders own 0.49% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TEVA. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Scotiabank lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a report on Thursday, January 29th. Bank of America boosted their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Truist Financial increased their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Finally, Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus target price of $37.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.